Healthcare [ 13/13 ] | Drug Manufacturers - Specialty & Generic [ 100/164 ]
NASDAQ | Common Stock
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally.
The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder.
The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults.
In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics.
Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose.
It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder.
The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | 0.34 Decreased by -15.30% | 0.41 Decreased by -17.37% |
| Feb 22, 24 | 0.43 Increased by +132.07% | 0.28 Increased by +53.57% |
| Nov 9, 23 | -0.98 Decreased by -450.00% | 0.30 Decreased by -426.67% |
| Jul 27, 23 | 0.39 Increased by +13.50% | 0.22 Increased by +77.27% |
| Apr 27, 23 | 0.40 Increased by +45.35% | - |
| Feb 16, 23 | -1.34 Decreased by -638.26% | - |
| Oct 27, 22 | 0.28 Increased by +86.67% | - |
| Jul 28, 22 | 0.34 Decreased by -14.10% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 284.00 M Increased by +12.25% | 47.00 M Increased by +6.82% | Increased by +16.55% Decreased by -4.84% |
| Dec 31, 23 | 293.00 M Increased by +21.58% | 54.00 M Increased by +129.51% | Increased by +18.43% Increased by +124.27% |
| Sep 30, 23 | 271.00 M Increased by +16.81% | -135.00 M Decreased by -429.27% | Decreased by -49.82% Decreased by -381.88% |
| Jun 30, 23 | 276.00 M Increased by +24.89% | 39.00 M Decreased by -18.75% | Increased by +14.13% Decreased by -34.94% |
| Mar 31, 23 | 253.00 M Increased by +22.22% | 44.00 M Increased by +7.32% | Increased by +17.39% Decreased by -12.20% |
| Dec 31, 22 | 241.00 M - | -183.00 M - | Decreased by -75.93% - |
| Sep 30, 22 | 232.00 M - | 41.00 M - | Increased by +17.67% - |
| Jun 30, 22 | 221.00 M - | 48.00 M - | Increased by +21.72% - |